ContraFect announces several publications highlighting the

0

YONKERS, NY, Sept. 12, 2022 (GLOBE NEWSWIRE) — ContraFect Corporation (Nasdaq: CFRX)a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysines and amurine peptides, as novel medical modalities for the treatment of life-threatening, drug-resistant infections antibiotics, today announces the publication of an editorial in the Journal of Bone and Joint Infections discuss the potential of each of the Company’s lysines, exebacase and CF-296, as additional agents in the bone and joint infection (BJI) armamentarium due to their in vitro activity against coagulase-negative staphylococci (CoNS), the bacteria most frequently implicated in implant-associated BJI, and their potential for local and systemic anti-biofilm activity. The authors conclude that these benefits may outweigh the treatment difficulties with current antibiotic treatments for staphylococcal BJI alone.

A second publication in Antimicrobial agents and chemotherapya leading peer-reviewed journal devoted to the study of treatments for infectious diseases, presents the results of a study evaluating the in vitro activity of exebacase against biofilms formed by clinical strains of Staphylococcus epidermidis (S. epidermidis), a species of CoNS, commonly isolated from patients with prosthetic joint infections. Exebacase showed significant anti-biomass and bactericidal activity against S. epidermidis biofilms, as well as synergistic effects in addition to rifampicin, vancomycin and daptomycin.

“The activity we saw with exebacase in vitro, live, and in cases of compassionate use as recently presented by Dr. Tristan Ferry of the Hôspices Civils de Lyon in Lyon, France, at the 40th annual meeting of the European Bone and Joint Infection Society, provides a complete picture of the potential impact that exebacase could have for patients with osteomyelitis and prosthetic joint infections, which are particularly difficult to treat with current care antibiotic agents,” said Roger J. Pomerantz, MD, President , CEO and Chairman of the Board of ContraFect. “Prosthetic joint infections are particularly problematic, often requiring removal and reimplantation of the joint. As stated in the editorial, no randomized clinical trials in the area of ​​BJI have been performed. Given the strength of the data we have accumulated to date, we believe that a randomized clinical study of exebacase in patients with chronic or recurrent prosthetic joint infections caused by MRSA or S. epidermidis may be the first blinded, randomized trial in this area,” Dr. Pomerantz added.

About ContraFect:

ContraFect is a biotechnology company focused on the discovery and development of DLA, including lysines and amurine peptides, as novel medical modalities for the treatment of life-threatening, antibiotic-resistant infections. It is estimated that 700,000 deaths worldwide each year are attributed to antimicrobial resistant infections. We intend to treat life-threatening infections using our therapeutic product candidates from our DLA platform, which include lysines and amurine peptides. Lysines are a novel class of DLAs that are recombinantly produced antimicrobial proteins with a novel mechanism of action associated with rapid killing of target bacteria, eradication of biofilms, and synergy with conventional antibiotics. Amurine peptides are a novel class of DLAs that exhibit broad-spectrum activity against a wide range of antibiotic-resistant Gram-negative pathogens, including P. aeruginosa, Acinetobacter baumanniiand Enterobacter species. We believe that the properties of our lysines and amurine peptides will make them suitable for targeting antibiotic resistant organisms, such as MRSA and P. aeruginosa, which can cause serious infections such as bacteremia, pneumonia and osteomyelitis. We have completed a Phase 2 clinical trial for the treatment of Golden Staph bacteremia, including endocarditis, with our lead lysine candidate, exebacase, which is the first lysine to enter clinical studies in the United States. in addition to SOC anti-staphylococcal antibiotics.

Follow ContraFect on Twitter @ContraFectCorp and LinkedIn.

Forward-looking statements

This press release contains, and our officers and representatives may make from time to time, “forward-looking statements” within the meaning of the United States federal securities laws. Forward-looking statements can be identified by words such as “projects”, “may”, “will”, “could”, “would”, “should”, “believe”, “expect”, “anticipate”, “estimates,” “intends,” “expects,” “potential,” “promises,” or similar references to future periods. Examples of forward-looking statements contained in this release include, but are not limited to, statements regarding releases, in vitro study results, whether the benefits of exebacase and CF-296 could outweigh the therapeutic challenges of current antibiotic treatments for staphylococcal BJI alone, statements by Dr. Pomerantz, ContraFect’s ability to discover and develop the DLA as new medical modalities for the treatment of life-threatening and antibiotic-resistant infections, whether ContraFect will treat life-threatening infections using therapeutic candidates from its DLA platform, whether lysines are a new class of DLA that are produced recombinantly , antimicrobial proteins with a novel mechanism of action associated with rapid killing of target bacteria, eradication of biofilms, and synergy with conventional antibiotics, if amurines are a novel class of DLAs that exhibit broad-spectrum activity against a wide range of antibiotic-resistant Gram-negative pathogens otics, and whether the properties of ContraFect’s lysines and aurines will make them suitable for targeting organisms resistant to ms antibiotics, such as MRSA and P. aeruginosa. Forward-looking statements are statements that are not historical facts or guarantees of future performance. Instead, they are based on ContraFect’s current beliefs, expectations and assumptions regarding the future of its business, future plans, strategies, projections, expected events and trends, the economy and other conditions. future. Because forward-looking statements relate to the future, they are subject to inherent risks, uncertainties and changes in circumstances that are difficult to predict and many of which are beyond ContraFect’s control, including the occurrence of any event adverse events related to the discovery, development, and commercialization of ContraFect’s product candidates such as adverse clinical trial results, insufficient pharmaceutical supplies, lack of regulatory approval, or failure to obtain or continued patent protection and other material risks detailed under “Risk Factors” in ContraFect’s Quarterly Report on Form 10-Q for the three months ended June 30, 2022 and its other filings with the Securities and Exchange Commission. Actual results may differ from those set forth in forward-looking statements. Any forward-looking statement made by ContraFect in this press release is based solely on information currently available and speaks only as of the date on which it is made. Except as required by applicable law, ContraFect expressly disclaims any obligation to publicly update any forward-looking statements, written or oral, which may be made from time to time, whether as a result of new information, future developments or other.

Investor Relations Contacts:

Michael Messinger
ContraFect Corporation
Email: mmessinger@contrafect.com

Share.

Comments are closed.